3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Colorectal Neoplasms
28
Gastrointestinal Stromal Tumors
4
Colonic Neoplasms
4
Carcinoma, Hepatocellular
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
3
Neoplasm Metastasis
3
Rectal Neoplasms
2
Gallbladder Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bile Duct Neoplasms
2
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Sarcoma
1
Rhabdomyosarcoma
1
Renal Insufficiency
1
Physician Education
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Noonan Syndrome 6
1
Metastatic Pancreatic Adenocarcinoma
1
Melanoma
1
Liver Neoplasms
1
Liposarcoma
1
Insulinoma
1
Interventions
Nivolumab
4
pertuzumab
2
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Docetaxel
2
Capecitabine
2
ulocuplumab
1
tremelimumab
1
tazarotene
1
talazoparib
1
romiplostim
1
pexidartinib
1
pamiparib
1
onartuzumab
1
magrolimab
1
entrectinib
1
cobimetinib
1
atezolizumab
1
Sunitinib
1
Rifampin
1
Ramucirumab
1
Radiosurgery
1
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
1
Midazolam
1
MK-4166
1
LY3022855
1
LY2510924
1
LY-2157299
1
Itraconazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Solid Tumor
×
regorafenib
×
Clear all
No trials found.